NasdaqGM - Nasdaq Real Time Price USD

RxSight, Inc. (RXST)

12.64

-0.56

(-4.24%)

As of 12:41:22 PM EDT. Market Open.

Medical Technology Firms Face Price Target Revisions From Morgan Stanley

Morgan Stanley has revised the price targets of a number of medical technology firms in a Tuesday no

PREMIUM
MT Newswires yesterday

RXST
-4.24%
RxSight, Inc. (NASDAQ:RXST) Just Reported Earnings, And Analysts Cut Their Target Price

It's been a mediocre week for RxSight, Inc. ( NASDAQ:RXST ) shareholders, with the stock dropping 18% to US$13.06 in...

Simply Wall St. 4 days ago

RXST
-4.24%
RxSight Inc (RXST) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Advances Amid ...

RxSight Inc (RXST) reports a 28% revenue increase and strategic progress, despite facing macroeconomic headwinds and competitive pressures.

GuruFocus.com 6 days ago

RXST
-4.24%
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates

RxSight (RXST) delivered earnings and revenue surprises of 25% and 0.01%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 6 days ago

RXST
-4.24%

GMED
RxSight, Inc. Reports First Quarter 2025 Financial Results

ALISO VIEJO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2025. Key Quarterly Highlights Reported first quarter 2025 revenue of $37.9 million, an increase of 28% compared to the first quarter of 2024, reflecting: The sale of 27,579 Light Adjustable Lenses (LAL®/LAL+®), r

GlobeNewswire 6 days ago

RXST
-4.24%
CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

CVRx (CVRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 13 days ago

CVRX

RXST
-4.24%
RxSight, Inc. to Present at the Bank of America Healthcare Conference

ALISO VIEJO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference in Las Vegas. RxSight’s management is scheduled to present on Wednesday, May 14, 2025, at 3:40 p.m. Pacific Time / 6:40 p.m. Eastern Time. Interested parties may access a live and archived

GlobeNewswire 13 days ago

RXST
-4.24%
RxSight, Inc. (RXST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 14 days ago

RXST
-4.24%

IQV
What Does RxSight, Inc.'s (NASDAQ:RXST) Share Price Indicate?

While RxSight, Inc. ( NASDAQ:RXST ) might not have the largest market cap around , it received a lot of attention from...

Simply Wall St. 19 days ago

RXST
-4.24%
RxSight, Inc. to Report First Quarter 2025 Financial Results on May 7, 2025

ALISO VIEJO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the first quarter of 2025 after the market close on Wednesday, May 7, 2025. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference c

GlobeNewswire 20 days ago

RXST
-4.24%
JP Morgan downgrades RxSight on market, competitive pressures

Investing.com -- JP Morgan downgraded RxSight to Underweight, citing market, economic, and competitive headwinds that have led to a weaker-than-expected first-quarter performance and a downward revision to 2025 guidance. The firm set a $17 price target on the stock.

Investing.com last month

RXST
-4.24%
Block upgraded, Nvidia downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Morgan Stanley upgraded Block (XYZ) to Overweight from Equal Weight with a price target of $67, up from $65. The firm sees a “compelling” valuation at current share levels and low expectations for reaccelerated Square Seller growth. Cantor Fitzgerald upgraded Zscaler (ZS) to Overweight from Neutral wit

TipRanks last month

NVDA

ESI

FAST
Is RxSight, Inc. (NASDAQ:RXST) Trading At A 39% Discount?

Key Insights The projected fair value for RxSight is US$26.71 based on 2 Stage Free Cash Flow to Equity Current share...

Simply Wall St. last month

RXST
-4.24%
RxSight Inc (RXST) Q1 2025 Earnings Call Highlights: Strong Year-Over-Year Growth Amid Revised ...

Despite a 28% revenue increase, RxSight Inc (RXST) adjusts its full-year outlook due to macroeconomic challenges and market conditions.

GuruFocus.com last month

RXST
-4.24%
Preliminary Q1 2025 Rxsight Inc Earnings Call

Preliminary Q1 2025 Rxsight Inc Earnings Call

Thomson Reuters StreetEvents last month

RXST
-4.24%
RxSight Plunges 44% After Slashing 2025 Guidance; Bank of America Downgrades Stock

Q1 2025 revenue expected at $37.9 million, below the $39.6 million FactSet estimate.

GuruFocus.com last month

RXST
-4.24%
RxSight Q1 Revenue Miss, Guidance Cut Raise Growth Concerns, BofA Says

RxSight's (RXST) Q1 revenue shortfall and lower 2025 guidance raise concerns about slowing growth an

PREMIUM
MT Newswires last month

RXST
-4.24%
RxSight Warns On FY25 Revenue As Premium Cataract Market Faces Headwinds, Stock Plunges

RxSight, Inc. (NASDAQ:RXST) shares are trading lower premarket on Thursday. On Wednesday, the company disclosed first-quarter preliminary results and revised its FY25 outlook. The company sees first-quarter revenue of around $37.9 million, up 28% year over year and down 6% quarter over quarter, and below the consensus of $40.14 million. RxSight projects the sale of 27,579 Light Adjustable Lenses (LAL/LAL+), with a growth of 36%Y/Y increase in procedure volume. Also, the company anticipates the s

Benzinga last month

RXST
-4.24%
RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance

ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Thursday, April 3, 2025, at 8:00 a.m. Eastern Time. Preliminary First Quarter 2025 Results Preliminary first quarter 2025 r

GlobeNewswire last month

RXST
-4.24%
RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

ALISO VIEJO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 24th Annual Needham Virtual Healthcare Conference. RxSight’s management is scheduled to participate in a fireside chat on Tuesday, April 8, 2025, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. A live and archived webcast

GlobeNewswire last month

RXST
-4.24%

Performance Overview

Return	RXST	S&P 500 (^GSPC)
YTD	-63.23%	+0.13%
1-Year	-79.01%	+12.25%
3-Year	+2.02%	+46.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

RxSight, Inc. (RXST)

Medical Technology Firms Face Price Target Revisions From Morgan Stanley

RxSight, Inc. (NASDAQ:RXST) Just Reported Earnings, And Analysts Cut Their Target Price

RxSight Inc (RXST) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Advances Amid ...

RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates

RxSight, Inc. Reports First Quarter 2025 Financial Results

CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

RxSight, Inc. to Present at the Bank of America Healthcare Conference

RxSight, Inc. (RXST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

What Does RxSight, Inc.'s (NASDAQ:RXST) Share Price Indicate?

RxSight, Inc. to Report First Quarter 2025 Financial Results on May 7, 2025

JP Morgan downgrades RxSight on market, competitive pressures

Block upgraded, Nvidia downgraded: Wall Street’s top analyst calls

Is RxSight, Inc. (NASDAQ:RXST) Trading At A 39% Discount?

RxSight Inc (RXST) Q1 2025 Earnings Call Highlights: Strong Year-Over-Year Growth Amid Revised ...

Preliminary Q1 2025 Rxsight Inc Earnings Call

RxSight Plunges 44% After Slashing 2025 Guidance; Bank of America Downgrades Stock

RxSight Q1 Revenue Miss, Guidance Cut Raise Growth Concerns, BofA Says

RxSight Warns On FY25 Revenue As Premium Cataract Market Faces Headwinds, Stock Plunges

RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance

RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

Performance Overview